Leading the Way in Life Science Technologies

GEN Exclusives

More »

Best of the Web

More »
May 15, 2007 (Vol. 27, No. 10)

Biopeer

URL:www.biopeer.com
  • Well thought out
  • None
Biopeer fits somewhere in between a typical blog (blog = boring log) site about research biology and a news site. A real plus for Biopeer is that it avoids the shortcomings of both and makes for informed and focused reading. The opening page of the site has a teaser story illustrating how information is handled. The lead article at press time concerned recent discoveries linking obesity to the growth of cancer. The authors have written an encompassing set of descriptions relative to the headline and then linked text within them to the appropriate news article. In the wrong hands, this approach not only doesn’t work well, it actually turns away potential readers from the site. Fortunately, it is done superbly here. I’m impressed at the handling of the news, though the Ads by Google get a bit more prominent of a display than I would like. Other pluses for the site include the Hot Jobs section, archives, a nicely categorized section on Avian Flu, and more.
  • Key:
  • Strong Points
  • Weak Points
  • Ratings:
  • Excellent
  • Very Good
  • Good


*The opinions expressed are solely those of the author(s) and should not be construed as reflecting the viewpoints of the publisher, Genetic Engineering & Biotechnology News, Mary Ann Liebert, Inc., the publishing house, or employees and affiliates thereof.

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »